Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling
leading to impaired T-cell dependent antibody response
Stressors that exhibit immunosuppression might act by different mechanisms, i.e. alter
the number of cells involved in the immune response, the ability of the cells to produce
cytokines, chemokines, antibodies or growth factors, the composition of the subpopulations
of cells present at the site of the response, or the function of the cells. This Adverse
Outcome Pathway (AOP) describes how impairment of the signaling receptor IL-1R1 in
T cells can lead to impaired T cell activation and antibody production, leading to
increased susceptibility to infection. The AOP focuses on the blocking of binding
of IL-1 to IL-1R1, leading to the Inhibition of Nuclear factor kappa B (NF-kB). This
AOP is referred to as AOP 277 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki).
Published on October 23, 2023
In series:OECD Series on Adverse Outcome Pathwaysview more titles